Research In Latent Tuberculosis Infection (LTBI) in the Setting of HIV Co-Infection (R01)
Grant Amount: Unspecified.
The purpose of this FOA is to stimulate research about the role of microbiologic adaptive mechanisms, host immunologic factors, and their interactions in the development, maintenance, and re-activation of latent tuberculosis infections (LTBI) with a focus on HIV co-infection. Mechanisms of TB latency are poorly understood. LTBI occurs when Mycobacterium tuberculosis (MTB) persists in the host without signs of active disease, yet maintains the potential to cause active tuberculosis. HIV co-infection in people with latent MTB increases the risk of developing active disease from ten percent over a lifetime to ten percent per year. While ART reduces the increased risk for developing active TB, the risk remains elevated after a good response to antiretroviral therapy. While six to nine months of isoniazid (INH) therapy can significantly lower, and in some cases, eliminate the risk of reactivation disease, compliance with this prolonged regimen is often poor and usually cannot be effectively targeted to individuals at very high risk of reactivation. In addition, the use of the standard, nine-month course of INH for prevention of active TB in HIV-infected populations is effective only during therapy. TB risk increases soon after discontinuation, because of both reactivation of latent disease and re-infection.
Applications are encouraged both from investigators new to this area of research, with promising (even if few) preliminary data as well as from investigators interested in innovatively expanding current LTBI efforts to include HIV-infected populations and development of improved and relevant animal models. Investigators are encouraged to utilize existing NIAID resources (materials, in vitro and animal model testing, genomics, transcriptomics, proteomics, etc.) as appropriate to the research projects and to take advantage of existing clinical research cohorts and specimens.
This FOA will support studies that may lead to new assays and strategies to detect and quantitate latent MTB, predict or identify early reactivation, characterize drug resistance of latently infecting mycobacteria, and develop therapeutics (including immune-based therapy) to rapidly and effectively eradicate latent MTB organisms, in the context of HIV co-infection.
National Institute of Allergy and Infectious Diseases Division of AIDS
City Agencies Colleges/Universities Commercial Organizations Community Based Organizations County Agencies Educational Organizations/Institutions Federal Government Agencies International Agencies IRS 501 (c)(3) Organizations Nonprofit Organizations Religious Organizations Schools State Agencies Tribal Organizations
Award Amount Notes
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Application budgets are not limited, but need to reflect actual needs of the proposed project.
Application Due Date
Project Start Date
Grants.gov Customer Support , Phone: (800) 518-4726
Drug Resistance HIV Latent TB Medical Treatments and Therapies Persons with HIV/AIDS Research Programs TB Prevention
Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the “Apply for Grant Electronically” button in this FOA or following the directions provided at Grants.gov.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide (http://grants.nih.gov/grants/funding/424/SF424_RR_Guide_General_Adobe_VerB.pdf), except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.